Validity of the activPAL3 activity monitor in people moderately affected by Multiple Sclerosis by Coulter, E.H. et al.
 
 
 
 
Coulter, E.H. et al. (2017) Validity of the activPAL3 activity monitor in 
people moderately affected by Multiple Sclerosis. Medical Engineering and 
Physics, 45, pp. 78-82. (doi:10.1016/j.medengphy.2017.03.008) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/140080/ 
     
 
 
 
 
 
 
Deposited on: 11 May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 1 
 
Title: Validity of the activPAL3 activity monitor in people moderately affected by Multiple Sclerosis. 
 
Authors: Coulter EH a, b, Miller L c, d, McCorkell Sc, McGuire C e, Algie K f, Freeman Jf, Weller 
Be, Mattison PGc, McConnachie Ag, Wu Oh, Paul La 
a School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK; b School of 
Health Sciences, Queen Margaret University, Edinburgh, UK; c Multiple Sclerosis Service, 
NHS Ayrshire and Arran, Irvine, UK; d School of Health and Life Sciences, Glasgow Caledonian 
University, Glasgow, UK; e Anne Rowling Regenerative Neurology Clinic, NHS Lothian, 
Edinburgh, UK; f School of Health Professions, University of Plymouth, Plymouth, UK; g 
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK; h Institue of Health 
and Wellbeing, University of Glasgow, Glasgow, UK. 
 
Keywords: Validity; Accelerometer; Measurement; Multiple Sclerosis; Physical activity 
Corresponding Author 
Dr Elaine Coulter 1 
School of Health Sciences 
Queen Margaret University 
Queen Margaret Drive 
Musselburgh 
Edinburgh 
EH21 6UU 
UK 
Tel: +44 (0) 131 474 0000 
Email: ECoulter@qmu.ac.uk 
 
Co-authors 
Ms Linda Miller  
MS Service 
NHS Ayrshire and Arran  
Kilwinning Road 
Irvine 
                                                          
1
 Present address 
 2 
 
KA12 6SS 
UK 
Email: Linda.Renfrew@aapct.scot.nhs.uk 
 
Mrs Sara McCorkell  
MS Service 
NHS Ayrshire and Arran  
Kilwinning Road 
Irvine 
KA12 6SS 
UK 
Email: Sara.McCorkell@aapct.scot.nhs.uk 
 
Mrs Caroline McGuire 
Anne Rowling Regenerative Neurology Clinic 
49 Little France Crescent 
NHS Lothian 
Edinburgh 
EH16 4SB 
UK 
Email: carolinemcguire@nhs.net 
 
Mrs Kimberley Algie 
School of Health Professions 
University of Plymouth 
Derriford Road 
Plymouth 
PL6 8BH 
UK 
Email: kimberley.algie@plymouth.ac.uk 
 
Dr Jenny Freeman 
School of Health Professions 
University of Plymouth 
Derriford Road 
Plymouth 
PL6 8BH 
UK 
Email: J.Freeman-1@plymouth.ac.uk 
 
Dr Belinda Weller 
Anne Rowling Regenerative Neurology Clinic 
49 Little France Crescent 
NHS Lothian 
Edinburgh 
EH16 4SB 
UK 
 3 
 
Email: Belinda.Weller@nhslothian.scot.nhs.uk 
 
Dr Paul Mattison 
MS Service 
NHS Ayrshire and Arran  
Kilwinning Road 
Irvine 
KA12 6SS 
UK 
Email: paulmattison@nhs.net 
Dr Alex McConnachie 
Robertson Centre for Biostatistics 
University of Glasgow 
University Avenue 
Glasgow 
G12 8QQ 
UK 
Email: Alex.McConnachie@glasgow.ac.uk 
 
Professor Olivia Wu 
Institue of Health and Wellbeing 
University of Glasgow 
Lilybank Gardens 
Glasgow  
G12 8RZ 
UK 
Email: Olivia.Wu@glasgow.ac.uk 
 
Dr Lorna Paul 
School of Medicine, Dentistry and Nursing 
Oakfield Avenue 
University of Glasgow 
Glasgow 
G12 8LL 
UK 
Email: Lorna.Paul@glasgow.ac.uk 
 
 
 
 
 
 4 
 
Title: Validation of the activPAL3 activity monitor in people moderately affected by Multiple 
Sclerosis 
 
Abstract 
Background: Walking is the primary form of physical activity performed by people with 
Multiple Sclerosis (MS), therefore it is important to ensure the validity of tools employed to 
measure walking activity. The aim of this study was to assess the criterion validity of the 
activPAL3 activity monitor during overground walking in people with MS. 
Methods: Validity of the activPAL3 accelerometer was compared to video observation in 20 
people moderately affected by MS. Participants walked 20-30m twice along a straight quiet 
corridor at a comfortable speed.  
Results: Inter-rater reliability of video observations was excellent (all intraclass correlations 
> 0.99). The mean difference (activPAL3- mean of raters) was -4.70 ± 9.09, -4.55 s ± 10.76 
and 1.11 s ± 1.11 for steps taken, walking duration and upright duration respectively. These 
differences represented 8.7, 10.0 and 1.8% of the mean for each measure respectively. The 
activPAL3 tended to underestimate steps taken and walking duration in those who walked 
at cadences of ≤ 38 steps/minute by 60% and 47% respectively. 
Discussion: The activPAL3 is valid for measuring walking activity in people moderately 
affected by MS. It is accurate for upright duration regardless of cadence. In participants with 
slow walking cadences, outcomes of steps taken and walking duration should be interpreted 
with caution. 
Keywords: Validity; Accelerometer; Measurement; Multiple Sclerosis; Physical activity 
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Introduction 
Multiple Sclerosis (MS) is a life-long progressive condition which may affect mobility. 
Physical Activity (PA) can improve MS symptoms and overall physical and mental health [1]. 
Walking is the primary form of PA performed by people with MS. Therefore it is important 
to ensure measurement tools are accurate when measuring various parameters of walking 
activity. Physical activity can be measured using self-report questionnaires or with objective 
activity monitors. Subjective methods have the advantage of being  inexpensive and can be 
used in large samples, however, self-report is often subject to overestimation and 
difficulties with memory recall, particularly in inactive populations [2]. Measurement 
devices such as pedometers and accelerometers objectively monitor PA, providing a range 
of outcome measures such as activity counts, energy expenditure, steps taken, time spent 
walking and time spent sitting/lying. The accuracy of a number of devices has been 
investigated previously in those with MS [3–7]. The walking speeds or cadences at which the 
validity was assessed has been reported for only three devices, Actigraph (Model 7164), 
Actigraph (GT3X+ accelerometer) and the Step Activity Monitor [5,6]. These studies included 
participants with Expanded Disability Status Scale (EDSS) 0 (normal neurological exam) – 6.5 
(constant bilateral walking aids required to walk 20 m without resting) [8]. All three 
monitors were found to have low errors in step count. However, the slowest walking 
speeds/cadences reported, at which errors in measurement are more likely to occur, were 
0.9 m/s and 0.45 m/s or 85 steps/minute [5,6]. These walking speeds/cadences may be 
regarded as relatively fast for some people with MS. 
 
 6 
 
The activPAL3 is a second generation tri-axial accelerometer based upon the uni-axial 
activPAL (PAL Technologies Ltd, Glasgow, UK), providing measures such as steps taken, time 
spent walking, standing, upright (standing and walking) and sitting/lying and sit-to-stand 
transitions. The activPAL3 has a sampling frequency of 20Hz, compared to previous version’s 
10Hz, and has been found to be valid and reliable for healthy adults and children [9–11] 
with greater step detection than the original activPAL during activities of daily living [12]. 
The uni-axial activPAL has previously been found to have a greater than 30% error in steps 
taken in people with MS requiring uni-lateral or bilateral walking assistance to walk (EDSS 
6.0-6.5) compared to video observation as a criterion measure [3]. However, the protocol 
utilised included a range of activities of daily living where incidental steps taken may not 
have been detected by the monitor leading to large percentage errors in step count 
particularly when the total number of steps is small. In addition, the discrepancies in steps 
taken during the individual tasks were not reported. The second generation monitor, 
activPAL3, which consists of a tri-axial accelerometer with a higher sampling frequency may 
be more accurate than the uni-axial activPAL, particularly at slow walking speeds [13].  
 
Aim 
The aim of this study was to assess the criterion validity of the activPAL3 activity monitor for 
measuring steps taken, walking time and upright duration during overground walking in 
people moderately affected by MS. 
 
Methods 
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Participants  
People with MS were recruited from those already taking part in one site of the multi-centre 
WEBPaMS trial (ClinicalTrials.gov ref: NCT02508961). Potential participants from NHS 
Ayrshire and Arran were provided with information regarding the sub-study. To be included 
participants were required to have an EDSS of 4.0-6.5 [8]. Participants were excluded if they 
were unable to walk independently with or without aids. Ethical approval was obtained 
from the South Central-Oxford B Research Ethics Committee (Ref: 15/SC/0783) and all 
participants provided written informed consent. 
 
Instrument 
The activPAL3 (PAL Technologies Ltd, Glasgow, UK) is a single unit (2.4 x 4.3 x 0.5 cm3, 10g), 
tri-axial accelerometer with a sampling frequency of 20Hz. The activPAL3 was positioned on 
the anterior mid-thigh of the participants self-reported strongest or dominant leg and for 
the purposes of this study it was attached using micropore tape. 
 
Procedures  
Participants began the test sitting on a chair for two minutes. The participant was instructed 
to stand up, walk 20 - 30 m along a straight quiet corridor at a comfortable speed. 
Participants then stood quietly while a chair was positioned behind them. Participants were 
then instructed to sit for 1 minute following which the test was repeated. A video recorder 
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was used to video all walking and standing activities performed by participants, with the 
video focused on the lower half of the body.  
 
Three independent raters, who were experienced physiotherapists, assessed the video 
recordings.  Raters defined a step as occuring when the foot was lifted off the ground and 
placed in a new position. Walking time was defined as the time between first heel strike and 
double support standing and the end of the ‘walk’. Upright time was defined as the time 
between standing up from the chair with hips and knees extended until participants were 
again fully seated on the chair. Walking and total upright duration were measured using a 
stopwatch. The mean of the three raters results was used as the criterion measure. 
 
Data analysis      
Inter-rater reliability was assessed using Intraclass Correlation Coefficients (ICC) for absolute 
agreement. ICC values <0.4, 0.4-0.59, 0.60-0.74 and 0.75-1.00 were considered poor, fair, 
good and excellent respectively [14]. The activPAL3 data were downloaded using the 
manufacturer’s software (ActivPAL Professional Software version 7.2.23). Number of steps, 
walking and standing duration were extracted for each walking test. Differences between 
the activPAL3 and direct observation was assessed by the Bland-Altman method [15,16] and 
paired t-tests with a two-sided level of significance of 5% using SPSS version 22 (IBM Corp, 
Armonk, NY, USA). Outliers were defined as data points outwith the upper and lower limits 
of agreement on the Bland-Altman plots. Differences in results between the activPAL3 and 
the mean of the three raters are calculated as ‘activPAL3 – raters’ throughout. 
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Results  
Twenty participants were recruited (11 female, 9 male, mean age 53.7 ± 7.4 years). 
Participants had a range of EDSS levels [EDSS 4.0 (n=1), EDSS 4.5 (n=2), EDSS 5.5 (n=3), EDSS 
6.0 (n=7), EDSS 6.5 (n=7)]. The majority of participants (70%) used a walking aid and overall 
participants walked with a mean cadence of 83.9 ± 25.1 (25.5- 123.5) steps/minute (Table 
1). One participant was unable to complete both walking tests due to fatigue (Table 1). No 
data were lost during the study. 
 
Table 1 Near Here 
Raters 
The agreement between the three independent raters was excellent for steps (ICC= 0.995, 
95% CI 0.992, 0.997), walking duration (ICC= 0.999, 95% CI 0.998, 0.999) and total upright 
duration (ICC= 0.999, 95% CI 0.998, 0.999). For subsequent analyses, the mean values across 
the three raters was used for comparison with activPAL3 measures. 
 
Steps taken 
The mean difference in steps taken was -4.70 ± 9.09 with a maximum difference of 33 steps 
(Table 2). This mean difference represents an 8.7% underestimation from the activPAL3 
compared to the mean number of steps observed by the raters (53.8 steps). A paired t-test 
suggests that the difference in steps taken between the activPAL3 and the average of the 
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three raters is significantly different to zero (p=0.003, 95% CI -7.65, -1.76). The Bland-Altman 
method demonstrated lower and upper level of agreements of -22.88 and 13.47 steps 
respectively (Figure 1(a)). From the Bland-Altman, five clear outliers can be identified. These 
large differences between raters and the activPAL3 device in terms of steps taken were 
found in five walking events completed by the three participants (A112, A114 and A116) 
with EDSS 6.5 and walking cadences of 26, 38 and 53 steps/minute respectively. When the 
outliers are removed, the mean difference reduces to -3.75 ± 2.59 and the lower and upper 
limits of agreement narrow (-8.9 and 1.4 steps respectively) (Figure 1(a)). Differences in 
steps taken by participants with EDSS 6.0 and below are much lower with a maximum 
underestimation from the activPAL3 of 9 steps (Table 2; Figure 2(a)). 
 
Table 2 Near Here 
 
Figure 1 Near Here 
 
Figure 2 Near Here 
 
 
Walking duration 
The mean difference in walking duration was -4.55 s ± 10.76 with a maximum difference of 
47.18 s (Table 2). This mean difference represents a 10.0% underestimation from the 
activPAL3 compared to the mean walking duration observed (45.7 s). A paired t-test 
suggests that the difference in walking duration between the activPAL3 and the average of 
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the three raters is significantly different to zero (p=0.012, 95% CI -8.04, -1.06). The Bland-
Altman method demonstrated lower and upper level of agreements of -26.06 and 16.96 s 
respectively for walking duration (Figure 1(b)). Three outliers can be identified from the 
Bland-Altman plot. These large differences in walking duration were found in walking events 
completed by two participants (A112 and A114) with EDSS 6.5 and slow walking cadences 
(26 and 38 steps/minute). When the outliers are removed the mean difference in walking 
duration reduces to -1.60 s ± 2.04 and lower and upper limits of agreement narrow and 
become closer to zero (-5.7 and 2.5 s respectively) (Figure 1(b)). Differences in walking 
duration between the activPAL3 and the raters were much lower in participants with EDSS ≤ 
6.0 with a maximum difference of 4 s (Table 2; Figure 2(b)). 
 
Total upright duration 
The mean difference in upright duration was 1.11 s ± 1.11 with a maximum difference of 
3.84 s (Table 2). This mean difference represents a 1.8% overestimation by the activPAL3 
compared to the mean total upright time observed (61.8 s). A paired t-test suggests that the 
difference in walking duration between the activPAL3 and the average of the three raters is 
significantly different to zero (p≤0.001, 95% CI -1.48, -0.72). The Bland-Altman method 
demonstrated lower and upper level of agreements of -1.12 and 3.34 s respectively for 
upright duration (Figure 1(c)). Two outliers (3.84 s and -2.45 s) can be identified from the 
Bland-Altman plot. These differences were found in events completed by two different 
participants (A107 and A127). Differences in upright time for the second walking tests 
completed by these participants were smaller with 2.17 s and 0.56 s respectively. When the 
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outliers are removed the limits of agreement narrow (-0.60 and 2.86). The activPAL3 was 
accurate for upright duration for all participants regardless of average cadence (Figure 2(c)).  
 
Discussion  
The results of this study demonstrate that the activPAL3 is valid for measuring walking 
activity in people moderately affected by MS (EDSS 4-6.5). Walking is the main form of PA 
performed by people with MS and the primary outcome of interest in many rehabilitation 
studies. As such, use of a valid measurement tool is of great importance.  
 
The activPAL3 tended to underestimate steps taken and walking duration in participants 
with relatively slow cadences. These differences are due to the activPAL3 misclassifying 
walking periods as standing events. For instance, it registered between two and four 
separate standing events lasting between 6.9 s and 12.8 s each while these participants 
were walking. This is likely to be attributed to the lower acceleration of the thigh during the 
swing phase of gait that does not exceed the threshold required by the activPAL3 to register 
a step had taken place. At these slow cadences the activPAL3 underestimated steps and 
walking duration by as much as 60% and 47% respectively. Therefore, walking measured 
using the activPAL3 in people with slow cadences should be interpreted with caution. Other 
devices have also experienced errors in steps taken at slow cadences. For instance, the 
Actigraph (Model 7164) was found to have a 4 ± 9% error in steps taken at 0.9 m/s and the 
Actigraph (GT3X+ accelerometer) was found to have a 12.7% error at average walking 
speeds of 0.45 ± 0.18 m/s or 85 steps/minute [5,6]. Recently, the accuracy of the activPAL3 
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was assessed in healthy adults walking slowly on a treadmill [10]. At a cadence of 69 
steps/minute 90% of steps were detected, while at 0.1 m/s or below 24 steps/minute zero 
steps were detected [10].  The cadences in some participants with EDSS 6.5 within the 
present study were particularly slow (38 and 26 steps/minute) and therefore inaccuracies 
are to be expected. The validity of walking duration has not been assessed in other devices 
in people with MS. As such comparisons between devices cannot be made for this outcome. 
 
The activPAL3 was accurate for upright duration for all participants with an average 
difference of 1.11 ± 1.11 s (1.8% error). Although two outliers were identified these were 
found in two different participants (EDSS levels 5.5 and 6.5) and these errors did not appear 
to be due to slow cadence or disability level. When these outliers were removed the 
changes to the mean, standard deviation and limits of agreement were minimal. Due to the 
activPAL3’s unique position on the thigh it is also capable of accurately classifying posture 
and sedentary time and providing measures of sit-to-stand transitions [17,18]. It is possible 
that for people with very slow cadences, outcomes of upright duration, sit-to-stand 
transitions and sedentary time may be valid since these outcomes have been found to be 
accurate regardless of walking speed in older people with impaired function [19]. In 
contrast, the Actigraph monitors cannot accurately measure posture classification [20]. 
Therefore, these additional outcomes generated from the activPAL3 may be of particular 
use for those with slow walking cadences.  
 
Limitations 
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The study has a number of limitations. The study involved a small sample of 20 participants 
who only completed two short linear walks. In addition, one participant was only able to 
complete one walk due to fatigue.  When the sample is considered by EDSS the numbers in 
each group are small. While it was possible to accurately estimate the mean bias for the 
majority of participants, our sample was not sufficient to determine the lower cut-off for 
walking cadence. Future studies could use an adaptive design to recruit participants until a 
sufficiently precise description of the EDSS and cadence bias association can be established. 
Validity was assessed during a controlled testing protocol in which participants walked in a 
straight line indoors. It is possible that greater errors would have been present if walking 
had been assessed in the free-living environment. However, walking events within this 
protocol were short and therefore it is possible that relatively smaller errors over longer 
walking events may be found.  
 
The activPAL3 is valid for measuring walking activity in people moderately affected by MS. It 
is accurate for upright duration regardless of cadence. In participants with slow walking 
cadences, outcomes of steps taken and walking duration should be interpreted with 
caution. 
 
Conclusion 
The activPAL3 is valid for measuring walking activity in people moderately affected by MS. 
Small but statistically significant differences were demonstrated for measuring steps taken, 
walking and upright duration. The activPAL3 underestimated steps and walking duration in 
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those with slow cadences of less than 38 steps/minute while upright duration was accurate 
for all participants regardless of walking cadence.  
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Legends to Tables and Figures 
Table 1. Characteristics of participants and maximum step difference between activPAL3 
and the average of three independent raters.  
 
Table 2. Summarised results, in relation to level of disability for differences in steps taken, 
walking and upright duration.  
 
Figure 1. Bland-Altman plots for (a) number of steps taken; (b) walking duration; (s) upright 
duration; vs differences between activPAL3 and the raters (activPAL3- raters).  
Solid lines indicate mean, upper and lower limits of agreement. Dotted lines indicate mean, upper 
and lower limits of agreement with outliers removed. 
 
Figure 2. Differences in (a) steps taken, (b) walking duration, and (c) upright duration by 
walking cadence.  
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Table 1. Characteristics of participants and maximum step difference between activPAL3 
and the average of three independent raters.  
Participant Gender Age EDSS Walking aid 
Average 
cadence 
(steps/min) 
 
Maximum  
difference in 
steps 
A117 M 51 4.0 None 83.7 3 
A121 F 52 4.5 None 113.2 4 
A128 F 51 4.5 None 109.2 2 
A118 F 48 5.5 None 121.1 3 
A124 F 47 5.5 None 111.6 4 
A127 F 59 5.5 None 82.1 7 
A123 M 44 6 1 stick 107.2 8 
A126 M 62 6 1 stick 106.7 4 
A119 M 63 6 1 stick 94.6 3 
A108 M 60 6 1 stick 94.2 8 
A129 M 42 6 1 stick 84.5 7 
A106 M 64 6 1 stick 84.4 2 
A113 F 48 6 1 stick 79.7 9 
A107 M 64 6.5 4 wheeled walker 86.3 4 
A103 M 63 6.5 3 wheeled walker 68.0 5 
A122 F 46 6.5 4 wheeled walker 59.1 3 
A116 F 46 6.5 4 wheeled walker 53.2 19 
A101 F 54 6.5 2 sticks 47.3 8 
A112 F 59 6.5 4 wheeled walker 37.6 33 
A114 F 49 6.5 2 crutches 25.5* 28 
*Only completed one walk due to fatigue. 
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Table 2. Summarised results, in relation to level of disability for differences in steps taken, 
walking and upright duration.  
Total number 
of events 
(n=39) 
Average cadence 
(steps/min) 
Difference in 
steps taken 
Difference in 
walking duration (s) 
Difference in 
upright duration (s) 
EDSS 4.0 
(n=2) 
83.7 ± 2.3 
(82.0, 85.3) 
-0.50 ± 3.53 
(-3.00, 2.00) 
0.89 ± 4.67 
(2.41, 4.19) 
1.57 ± 0.03 
(1.55, 1.59) 
EDSS 4.5 
(n=4) 
111.2 ± 2.5 
(108.2, 113.8) 
-2.83±1.60 
(-4.33, -1.00) 
-0.61 ± 2.92 
(-3.03, 3.32) 
0.31 ± 0.52 
(-0.46, 0.67) 
EDSS 5.0 
(n=0) 
- - - - 
EDSS 5.5 
(n=6) 
104.9 ± 18.3 
(81.4, 123.5) 
-3.50 ± 1.87 
(-7.00, -2.00) 
-1.41 ± 0.50 
(-1.95, -0.81) 
0.62 ± 1.81 
(-2.45, 2.69) 
EDSS 6.0  
(n=14) 
93.1 ± 10.7 
(79.0, 109.2) 
-4.31 ± 3.02 
(-9.00, 0.33) 
-1.92 ± 1.37 
(-4.05, 1.29) 
0.88 ± 0.54 
(0.20, 2.27) 
EDSS 6.5  
(n=13) 
56.0 ± 18.1 
(25.5, 86.9) 
-6.90 ± 15.44 
(-33.33, 19.00) 
-10.88 ± 17.14 
(-47.18, 4.21) 
1.77 ± 1.13 
(0.04, 3.84) 
Total  
 
83.9 ± 25.1 
(25.5- 123.5) 
-4.70± 9.09 
(-33.33, 19.00) 
-4.55 ± 10.76 
(-47.18, 4.21) 
1.11 ± 1.11 
(-2.45, 3.84) 
Mean ± standard deviation (range) 
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Figure 1. Bland-Altman plots for (a) number of steps taken; (b) walking duration; (s) upright 
duration; vs differences between activPAL3 and the raters (activPAL3- raters).  
Solid lines indicate mean, upper and lower limits of agreement. Dotted lines indicate mean, upper 
and lower limits of agreement with outliers removed. 
-40
-30
-20
-10
0
10
20
30
40
0 20 40 60 80 100
D
if
fe
re
n
ce
 in
 s
te
p
s 
ta
ke
n
  
Number of steps taken 
-60
-40
-20
0
20
40
60
0 20 40 60 80 100 120 140
D
if
fe
re
n
ce
 in
 w
al
ki
n
g 
d
u
ra
ti
o
n
 (
s)
 
Walking duration (s) 
-10
-5
0
5
10
0 20 40 60 80 100 120 140
D
if
fe
re
n
ce
 in
 u
p
ri
gh
t 
d
u
ra
ti
o
n
 (
s)
 
Upright duration (s) 
(a) 
(c) 
(b) 
 22 
 
 
Figure 2. Differences in (a) steps taken, (b) walking duration, and (c) upright duration by 
walking cadence.  
 
 
-50
-40
-30
-20
-10
0
10
20
30
40
50
0 20 40 60 80 100 120 140
D
if
fe
re
n
ce
 in
 s
te
p
s 
ta
ke
n
 
-50
-40
-30
-20
-10
0
10
20
30
40
50
0 20 40 60 80 100 120 140
D
if
fe
re
n
ce
 in
 w
al
ki
n
g 
d
u
ra
ti
o
n
 (
s)
 
-50
-40
-30
-20
-10
0
10
20
30
40
50
0 20 40 60 80 100 120 140
D
if
fe
re
n
ce
 in
 u
p
ri
gh
t 
d
u
ra
ti
o
n
 (
s)
 
Average cadence (steps/min) 
(a) 
(b) 
(c) 
 23 
 
Highlights 
 The criterion validity of the activPAL3 accelerometer in comparison to video 
observation was assessed in people with Multiple Sclerosis.  
 The activPAL3 underestimated steps and walking duration in those with slow 
cadences of less than 38 steps/minute 
 The activPAL3 was accurate for measuring upright duration regardless of walking 
cadence 
 
